Inrig Jula's Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed Jan 6, 2025
- Accession no.
- 0001415889-25-000899
- Filed
- Jan 6, 2025
- Trade date
- Jan 3-6, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $47.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Inrig JulaCIK 0001902368 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | Common Stock | SSaleDisposed | −2,066 | $19.10 | −$39,460.6 | 59,883 | Direct | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −440 | $18.76 | −$8,254.4 | 59,443 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.